U.S. FTC approves Hikma deal for Custopharm with conditions

Generic drug maker Hikma Pharmaceuticals has won U.S. antitrust approval to buy Custopharm, Inc on condition that it divest an injectable steroid, the U.S. Federal Trade Commission said on Tuesday. https://www.nasdaq.com/articles/u.s.-ftc-approves-hikma-deal-for-custopharm-with-conditions